Neotropix Logo.. Clinical Trials Home   Site Map   Search   Contact Us
About Neotropix Products Technology Partnering News and Events Careers


NeotropixDiscover. Develop. Deliver.
Realizing the Promise.

Neotropix™ Inc. develops and commercializes systemically deliverable oncolytic viruses for the treatment of neuroendocrine cancers, such as small cell lung cancer and neuroblastoma. Capitalizing on its unique sources of naturally occurring viruses that selectively target tumors, the Company has the knowledge and skills to translate these discoveries into commercial products. Neotropix is committed to discovering innovative cancer treatments that make a difference in the lives of cancer patients.

Neotropix A Leading Biotechnology Company Committed to Making a Difference in the Lives of Cancer Patients Through Innovative Lung Cancer Treatments & Much More!


Inside Neotropix

Many viruses have evolved, over billions of years, to do exactly what is needed to create effective cancer therapies: kill tumor cells but not normal cells. Neotropix works to harness viruses' natural properties to treat cancer and other diseases that are resistant to available therapeutic methods.

Neotropix began a Phase I/IIa Clinical Trial on our first cancer drug candidate in May, 2006.

We urge you to explore Neotropix and learn about our work in small cell lung cancer and other cancers as a leading biotechnology company in the emerging field of virotherapy.

Neotropix is at the forefront of research and treatment in specific areas such as small cell lung cancer, neuroendocrine non-small cell lung cancer, (including large cell lung cancer), carcinoid and multiple pediatric cancers, such as neuroblastoma, rhabdomyosarcoma, retinoblastoma, medulloblastoma, glioblastoma, rhabdoid tumors, and Wilms’ tumors.

Product Spotlight

NTX-010: NTX-010 is a novel naturally-occurring virus that is being developed as an innovative cancer treatment.  NTX-010 specifically attacks and kills neuroendocrine cancers, such as small cell lung cancer, small cell carcinomas originating in other organs, carcinoid, neuroblastoma and certain other neuroendocrine cancers.

Read More.



Recent News

July 22, 2011 - NCCTG Phase II study of NTX-010 in extensive-stage SCLC (Protocol N0923) activated on Cancer Trials Support Unit website

Feb 8, 2010 - Children's Oncology Group activates Phase I study of NTX-010 in neuroendocrine pediatric cancers

Jan 15, 2010 - North Central Cancer Treatment Group activates Phase II study of NTX-010 in extensive-stage SCLC

October 8, 2008 -Scripps research team solves structure of 'beneficial' virus


Oct, 2008 - NCI-supported Pediatric Preclinical Testing Program to present testing results with SVV-001 (NTX-010) at the 20th EORTC-NCI-AACR symposium on "Molecular Targets and Cancer Therapeutics" in Geneva, Switzerland (October 21-24, 2008)

NANETS - 2008 Neuro Endocrine Tumor Symposium


October 13,2008 - Venkataraman S, Reddy PS, Loo J, Idamakanti N, Hallenbeck PL, Reddy VS. Structure of Seneca Valley Virus-001: An Oncolytic Picornavirus Representing a New Genus. Structure. 2008. 16:1555-1561.

November, 2007: Seneca Valley Virus and the Treatment of Neuroendocrine Cancers

Press Releases

May 14, 2010 - Neotropix Announces Enrollment of Patients in NCI-Sponsored Phase II Clinical Trial for Small Cell Lung Cancer

January 14, 2009 - Frost & Sullivan Recognizes Neotropix's Approach to the Treatment of Small Cell Lung Cancer and Neuroendocrine Cancers

October 22, 2008 - Neotropix® Announces Presentation of Relevant Preclinical Results of NTX-010 in Pediatric Oncology Models

October 8, 2008 -Scripps research team solves structure of 'beneficial' virus

October 8, 2008 - Neotropix® Announces Expansion of On-going Clinical Trial
for Adult Neuroendocrine Cancers

September 23, 2008 - Neotropix Appoints Anthony Williams, M.D., as its Chief Medical Officer

May 17, 2006 - Neotropix Receives FDA Approval to Begin Clinical Trials With First Investigational Cancer Drug (PDF)


© 2008 Neotropix
© Copyright 2011 Neotropix. All Rights Reserved